摘要目的 通过检测凋亡抑制蛋白Livin在非小细胞肺癌患者、肺炎患者及健康者血清中的含量,探讨Livin对于诊断非小细胞肺癌的临床意义.方法 采用酶联免疫吸附试验对85例非小细胞肺癌患者、20例肺炎患者、20名正常健康人血清Livin水平进行检测.结果 非小细胞肺癌组血清Livin水平表达最高,肺炎组次之,健康对照组最低.三组间具有显著差异(P＜0.001).血清Livin浓度随着肿瘤分期的升高而升高.Ⅲ～Ⅳ期非小细胞肺癌患者血清Livin水平高于Ⅰ～Ⅱ期患者(P＜0.05).结论 Livin作为一种凋亡抑制蛋白对非小细胞肺癌的诊断及判断患者预后具有一定的临床价值.

abstractsObjective To investigate the clinical significance of Livin in the diagnosis of non-small cell lung cancer (NSCLC) through testing the content of inhibitor of apoptosis protein Livin in the serum of NSCLC patients, pneumonia patients and healthy persons. Methods Livin levels in the serum of 85 NSCLC patients, 20 pneumonia patients and 20 healthy persons were detected by enzyme linked immunosorbent assay. Results Livin level in the serum of NSCLC patients was significantly higher than that in pneumonia patients and healthy persons. The serum Livin level was increased following with tumor progress. Livin level in NSCLC patients with stage Ⅲ-Ⅳ was higher than that in NSCLC patients with stage Ⅰ - Ⅱ ( P ＜0.05) . Conclusions As an inhibitor of apoptosis protein,Livin has certain clinical value on the diagnosis and prognosis judgement of NSCLC patients.